PFE – Pfizer Inc.
Healthcare | Drug Manufacturers - General | Website
Quick Stats
Trend Overview
PFE has just crossed the 21-day EMA at $27.67, now trading above the line. Bulls have reclaimed a key reference. Whether this becomes a sustained move or a failed breakout depends on momentum confirming in the sessions ahead.
The cross is a signal, not a confirmation. Watch for a successful retest of the EMA21 from above – that would be the higher-confidence entry.
PFE Price Chart
Technical Trend Analysis
As of 07.10.2026 · Close: $28.00 · ATR14: $1.91
PFE has just crossed the 21-day EMA at $27.67, now trading above the line. Bulls have reclaimed a key reference. Whether this becomes a sustained move or a failed breakout depends on momentum confirming in the sessions ahead.
The cross is a signal, not a confirmation. Watch for a successful retest of the EMA21 from above – that would be the higher-confidence entry.
| Indicator | Signal | Detail |
|---|---|---|
| Swing Trend | ▲ Long | Primary directional bias |
| Momentum | ▼ Down · -3d | Strength: -0.13 – Fading |
| Trend Strength (ADX) | 6.5 – Weak | ADX38: 20.4 |
| Volatility (HV30) | 15.8% – Calm | HV90: 20.6% | HV180: 21.4% |
| Vola Compression | None | Normal range |
| MA Structure | Golden Cross ✓ | Stack: Mostly aligned (2/3) |
| EMA21 Distance | ~0 ATR – Near line | EMA21: $27.67 |
| GD200 Extension | 3.1 ATR – Normal | GD20: 0.1 | GD50: 1.0 | GD100: 3.4 |
Monthly Performance History
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2010 | -1.41 | -5.70 | -3.44 | -2.15 | -9.04 | -4.85 | 5.38 | 3.91 | 5.51 | 1.39 | -6.46 | 4.85 | -3.59 |
| 2011 | 3.01 | 1.13 | 6.12 | 2.88 | 3.07 | -2.11 | -7.18 | 1.02 | -6.48 | 11.04 | 4.85 | 8.04 | 27.46 |
| 2012 | -2.59 | -0.79 | 5.41 | 1.33 | -3.05 | 6.35 | 4.52 | -0.31 | 4.49 | -0.66 | 2.85 | -0.07 | 18.53 |
| 2013 | 6.19 | -0.98 | 5.41 | 0.75 | -5.00 | 0.97 | 6.06 | -3.05 | 2.60 | 6.22 | 2.57 | -3.77 | 22.17 |
| 2014 | -0.17 | 5.82 | 0.44 | -2.08 | -4.04 | -0.12 | -3.75 | 1.79 | 1.06 | 2.71 | 4.10 | -0.33 | 5.91 |
| 2015 | -0.27 | 9.37 | 0.05 | -1.18 | 2.83 | -2.96 | 7.06 | -10.15 | 0.16 | 6.21 | -5.78 | -3.97 | 6.47 |
| 2016 | -4.54 | -0.66 | -1.36 | 8.86 | 6.72 | 1.30 | 3.69 | -5.94 | -2.36 | -5.82 | 4.44 | 3.28 | 5.52 |
| 2017 | -3.85 | 7.75 | -0.64 | -0.92 | -2.42 | 2.72 | -1.94 | 3.53 | 5.13 | -2.78 | 3.76 | -0.34 | 14.11 |
| 2018 | 1.64 | -1.40 | -0.43 | 4.45 | 2.53 | 0.08 | 9.91 | 3.99 | 6.51 | -2.76 | 6.68 | -5.07 | 24.09 |
| 2019 | -0.99 | 1.09 | -2.06 | -5.19 | 2.73 | 3.32 | -11.27 | -7.07 |
T -0.52 |
T 8.32 |
1.31 | 2.30 | -6.04 |
| 2020 | -3.86 | -10.89 | -6.42 |
T 20.82 |
2.47 | -7.75 |
T 15.18 |
-1.44 | -0.49 |
T -2.43 |
T 12.59 |
-6.59 | 3.20 |
| 2021 | -1.41 | -6.45 |
T 7.50 |
6.47 | -1.80 | 1.72 |
T 9.19 |
4.79 | -6.59 | 1.88 |
T 24.22 |
7.99 | 66.69 |
| 2022 | -6.28 | -11.54 |
T 13.14 |
-4.85 |
T 10.61 |
T 0.12 |
-2.68 | -10.63 | -6.17 |
T 5.44 |
5.31 | 0.33 | -6.61 |
| 2023 | -13.05 | -7.74 | 1.52 |
T -5.94 |
-1.99 |
T -3.52 |
T -1.61 |
-0.65 | -7.29 | -9.96 | -0.13 | -0.42 | -32.07 |
| 2024 |
T -8.91 |
-2.67 |
T 4.36 |
-7.58 |
T 5.45 |
-4.54 |
T 8.22 |
-5.35 |
T 2.26 |
-1.29 | -6.69 |
T 2.75 |
-10.76 |
| 2025 | -0.34 | 0.88 |
T -3.47 |
-0.53 |
T -1.84 |
3.32 | -6.99 |
T 5.41 |
2.00 |
T -9.41 |
4.38 |
T -1.46 |
-6.43 |
| 2026 |
T 5.00 |
3.71 | 3.01 | -6.48 | -0.57 | -6.05 | 4.73 |
T 13.70 |
-0.11 | -0.43 | 11.20 |
T A T badge marks a Trendchange signal in that month. Hover for entry price.
PFE - Trendchange Chart
Trendchange Signal History
The last 10 Trendchange signals for PFE:
| Date | Entry Price | Days Held | +10d | +20d | +30d | +60d |
|---|---|---|---|---|---|---|
| 03.08.26 | $25.03 | 35d | +7.03% | +11.71% | +10.99% | +10.99% |
| 22.01.26 | $26.10 | 25d | +2.61% | +2.91% | +4.44% | +4.44% |
| 15.01.26 | $25.89 | 1d | +0% | +0% | +0% | +0% |
| 01.12.25 | $25.27 | 14d | +2.3% | -0.91% | -0.91% | +0% |
| 02.10.25 | $27.08 | 8d | -9.45% | -9.45% | -9.45% | -9.45% |
| 14.08.25 | $25.11 | 18d | -0.16% | -0.52% | -0.52% | +0% |
| 28.05.25 | $23.18 | 36d | +4.83% | +4.66% | +11.22% | +6.04% |
| 07.03.25 | $26.73 | 4d | -3.82% | -3.82% | -3.82% | -3.82% |
| 31.12.24 | $26.53 | 16d | -1.17% | -0.15% | -0.15% | -0.15% |
| 23.09.24 | $29.31 | 8d | -1.16% | -1.16% | -1.16% | -1.16% |
Signal Statistics - Historical Edge
Calculated edge for PFE: 6.97%
| Range | N | 10d | 20d | 30d | 60d | Signal |
|---|---|---|---|---|---|---|
| 10-15% | 4 | +10.49% | +20.19% | +19.82% | +20.06% | Hold |
| 7-10% | 7 | +7.94% | +8.05% | +8.89% | +10.3% | Hold |
| 5-7% | 10 | +5.66% | +5.66% | +7.23% | +7.79% | Hold |
| 3-5% | 17 | +3.75% | +4.75% | +6.21% | +6.15% | Close |
| 1-3% | 28 | +1.94% | +2.87% | +2.79% | +3.74% | Close |
| 0-1% | 7 | +0.67% | +0.07% | +0.22% | -0.21% | Close |
| -1-0% | 13 | -0.57% | +0.93% | +1.23% | +1.9% | Neg |
| -3-1% | 27 | -1.93% | -0.56% | -0.48% | +0.01% | Neg |
| -5-3% | 15 | -4.11% | -4.1% | -3.85% | -2.26% | Neg |
| -7-5% | 4 | -5.58% | -4.19% | -4.69% | -2.08% | Neg |
| -10-7% | 3 | -8.11% | -8.11% | -5.52% | -5.52% | Neg |
Signal data as of October 7, 2026
Options Metrics
Gamma Exposure Timeline
Key GEX levels, Max Pain, and unusual activity across weekly and monthly expirations, plotted around the current spot price.
Key GEX levels, Max Pain, Anchor, Ceiling and unusual activity across 14-30 DTE, plotted around the current spot price.
Put and call pins mark strikes where dealer gamma exposure concentrates. The GEX flip strike is where dealer hedging shifts from stabilizing (positive gamma) to amplifying (negative gamma) price moves. Max Pain is the strike where the most options expire worthless. Dashed markers flag unusual options activity. Learn how to use these signals in our options strategy guides →
View full options flow data and historical signals on the Options Flow Analysis Overview →
Valuation
| Metric | Value |
|---|---|
| Market Cap | $157.99 B |
| PE Ratio (TTM) | 36.47 |
| Forward PE | 9.57 |
| PEG Ratio | 12.68 |
| EV/EBITDA | 8.28 |
| Price/Sales | 2.48 |
| Price/Book | 1.85 |
| Beta | 0.30 |
Profitability
| Metric | Value |
|---|---|
| Gross Margin | 74.72% |
| Operating Margin | 27.88% |
| Net Margin | 6.80% |
| ROE | 5.01% |
| ROA | 5.78% |
Dividends
| Metric | Value |
|---|---|
| Annual Dividend | $1.72 |
| Forward Yield | 620.00% |
| Payout Ratio | 226.32% |
| Dividend Date | 2026-08-31 |
Analyst Consensus (26 Analysts)
| Metric | Value |
|---|---|
| Median Target | $28 |
| High Target | $35.75 |
| Low Target | $25 |
About Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
ETF Holdings
Pfizer Inc. is included in 2 ETFs tracked by StockBotty.